230 related articles for article (PubMed ID: 12612223)
1. Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase.
Davis JM; Parad RB; Michele T; Allred E; Price A; Rosenfeld W;
Pediatrics; 2003 Mar; 111(3):469-76. PubMed ID: 12612223
[TBL] [Abstract][Full Text] [Related]
2. Inhalation or instillation of steroids for the prevention of bronchopulmonary dysplasia.
Bassler D
Neonatology; 2015; 107(4):358-9. PubMed ID: 26044104
[TBL] [Abstract][Full Text] [Related]
3. Safety and pharmacokinetics of multiple doses of recombinant human CuZn superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome.
Davis JM; Rosenfeld WN; Richter SE; Parad MR; Gewolb IH; Spitzer AR; Carlo WA; Couser RJ; Price A; Flaster E; Kassem N; Edwards L; Tierney J; Horowitz S
Pediatrics; 1997 Jul; 100(1):24-30. PubMed ID: 9200356
[TBL] [Abstract][Full Text] [Related]
4. Late Surfactant Administration in Very Preterm Neonates With Prolonged Respiratory Distress and Pulmonary Outcome at 1 Year of Age: A Randomized Clinical Trial.
Hascoët JM; Picaud JC; Ligi I; Blanc T; Moreau F; Pinturier MF; Zupan V; Guilhoto I; Hamon IR; Alexandre C; Bouissou A; Storme L; Patkai J; Pomedio M; Rouabah M; Coletto L; Vieux R
JAMA Pediatr; 2016 Apr; 170(4):365-72. PubMed ID: 26928567
[TBL] [Abstract][Full Text] [Related]
5. Nasal CPAP or intubation at birth for very preterm infants.
Morley CJ; Davis PG; Doyle LW; Brion LP; Hascoet JM; Carlin JB;
N Engl J Med; 2008 Feb; 358(7):700-8. PubMed ID: 18272893
[TBL] [Abstract][Full Text] [Related]
6. Intratracheal budesonide mixed with surfactant to increase survival free of bronchopulmonary dysplasia in extremely preterm infants: statistical analysis plan for the international, multicenter, randomized PLUSS trial.
Francis KL; McKinlay CJD; Kamlin COF; Cheong JLY; Dargaville PA; Dawson JA; Doyle LW; Jacobs SE; Davis PG; Donath SM; Manley BJ
Trials; 2023 Nov; 24(1):709. PubMed ID: 37932774
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R;
Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381
[TBL] [Abstract][Full Text] [Related]
8. Prospective randomized multicenter comparison of high-frequency oscillatory ventilation and conventional ventilation in preterm infants of less than 30 weeks with respiratory distress syndrome.
Moriette G; Paris-Llado J; Walti H; Escande B; Magny JF; Cambonie G; Thiriez G; Cantagrel S; Lacaze-Masmonteil T; Storme L; Blanc T; Liet JM; André C; Salanave B; Bréart G
Pediatrics; 2001 Feb; 107(2):363-72. PubMed ID: 11158471
[TBL] [Abstract][Full Text] [Related]
9. A controlled trial of synthetic surfactant in infants weighing 1250 g or more with respiratory distress syndrome. The American Exosurf Neonatal Study Group I, and the Canadian Exosurf Neonatal Study Group.
Long W; Corbet A; Cotton R; Courtney S; McGuiness G; Walter D; Watts J; Smyth J; Bard H; Chernick V
N Engl J Med; 1991 Dec; 325(24):1696-703. PubMed ID: 1944470
[TBL] [Abstract][Full Text] [Related]
10. Treatment and outcome data of very low birth weight infants treated with less invasive surfactant administration in comparison to intubation and mechanical ventilation in the clinical setting of a cross-sectional observational multicenter study.
Langhammer K; Roth B; Kribs A; Göpel W; Kuntz L; Miedaner F
Eur J Pediatr; 2018 Aug; 177(8):1207-1217. PubMed ID: 29808237
[TBL] [Abstract][Full Text] [Related]
11. Inhaled nitric oxide in premature infants with the respiratory distress syndrome.
Schreiber MD; Gin-Mestan K; Marks JD; Huo D; Lee G; Srisuparp P
N Engl J Med; 2003 Nov; 349(22):2099-107. PubMed ID: 14645637
[TBL] [Abstract][Full Text] [Related]
12. The safety, pharmacokinetics, and anti-inflammatory effects of intratracheal recombinant human Clara cell protein in premature infants with respiratory distress syndrome.
Levine CR; Gewolb IH; Allen K; Welch RW; Melby JM; Pollack S; Shaffer T; Pilon AL; Davis JM
Pediatr Res; 2005 Jul; 58(1):15-21. PubMed ID: 15774846
[TBL] [Abstract][Full Text] [Related]
13. A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants.
Rastogi A; Akintorin SM; Bez ML; Morales P; Pildes RS
Pediatrics; 1996 Aug; 98(2 Pt 1):204-10. PubMed ID: 8692619
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of premature infants treated with prophylactic, intratracheal recombinant human CuZn superoxide dismutase.
Davis JM; Richter SE; Biswas S; Rosenfeld WN; Parton L; Gewolb IH; Parad R; Carlo W; Couser RJ; Baumgart S; Atluru V; Salerno L; Kassem N
J Perinatol; 2000 Jun; 20(4):213-6. PubMed ID: 10879331
[TBL] [Abstract][Full Text] [Related]
15. Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia.
Yeh TF; Chen CM; Wu SY; Husan Z; Li TC; Hsieh WS; Tsai CH; Lin HC
Am J Respir Crit Care Med; 2016 Jan; 193(1):86-95. PubMed ID: 26351971
[TBL] [Abstract][Full Text] [Related]
16. Multicenter controlled clinical trial of high-frequency jet ventilation in preterm infants with uncomplicated respiratory distress syndrome.
Keszler M; Modanlou HD; Brudno DS; Clark FI; Cohen RS; Ryan RM; Kaneta MK; Davis JM
Pediatrics; 1997 Oct; 100(4):593-9. PubMed ID: 9310511
[TBL] [Abstract][Full Text] [Related]
17. Outcome at twelve months of adjusted age in very low birth weight infants with lung immaturity: a randomized, placebo-controlled trial of human surfactant.
Vaucher YE; Harker L; Merritt TA; Hallman M; Gist K; Bejar R; Heldt GP; Edwards D; Pohjavuori M
J Pediatr; 1993 Jan; 122(1):126-32. PubMed ID: 8419599
[TBL] [Abstract][Full Text] [Related]
18. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome.
Hudak ML; Martin DJ; Egan EA; Matteson EJ; Cummings NJ; Jung AL; Kimberlin LV; Auten RL; Rosenberg AA; Asselin JM; Belcastro MR; Donohue PK; Hamm CR; Jansen RD; Brody AS; Riddlesberger MM; Montgomery P
Pediatrics; 1997 Jul; 100(1):39-50. PubMed ID: 9200358
[TBL] [Abstract][Full Text] [Related]
19. Hypocarbia before surfactant therapy appears to increase bronchopulmonary dysplasia risk in infants with respiratory distress syndrome.
Garland JS; Buck RK; Allred EN; Leviton A
Arch Pediatr Adolesc Med; 1995 Jun; 149(6):617-22. PubMed ID: 7767415
[TBL] [Abstract][Full Text] [Related]
20. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia.
Cole CH; Colton T; Shah BL; Abbasi S; MacKinnon BL; Demissie S; Frantz ID
N Engl J Med; 1999 Apr; 340(13):1005-10. PubMed ID: 10099142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
